LYELL IMMUNOPHARMA INC (LYEL)
US55083R1041 - Common Stock
ChartMill assigns a Buy % Consensus number of 80% to LYEL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 6.46. This target is 135.77% above the current price.
LYEL was analyzed by 10 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about LYEL.
In the previous month the buy percentage consensus was at a similar level.
LYEL was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-05-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-28 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2023-05-05 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-02 | HC Wainwright & Co. | Maintains | Buy |
| 2023-01-24 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-11-14 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2022-11-11 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2022-10-17 | HC Wainwright & Co. | Initiate | Buy |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |
| 2022-01-06 | Morgan Stanley | Maintains | Overweight |
| 2021-07-12 | JP Morgan | Initiate | Overweight |
| 2021-07-12 | Goldman Sachs | Initiate | Buy |
| 2021-07-12 | B of A Securities | Initiate | Buy |
| 2021-07-12 | Morgan Stanley | Initiate | Overweight |